Northern Trust Corp grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 331,500 shares of the company's stock after buying an additional 27,104 shares during the quarter. Northern Trust Corp owned approximately 0.68% of Enliven Therapeutics worth $7,459,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Tower Research Capital LLC TRC increased its stake in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after buying an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Enliven Therapeutics in the 4th quarter worth approximately $97,000. ExodusPoint Capital Management LP purchased a new position in Enliven Therapeutics in the 4th quarter worth approximately $200,000. China Universal Asset Management Co. Ltd. lifted its holdings in Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock worth $233,000 after purchasing an additional 1,275 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after purchasing an additional 1,980 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.
Enliven Therapeutics Trading Down 2.2%
Shares of ELVN stock traded down $0.37 on Friday, reaching $16.40. The company's stock had a trading volume of 222,508 shares, compared to its average volume of 259,958. The stock's fifty day simple moving average is $18.46 and its 200-day simple moving average is $21.25. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The company has a market capitalization of $804.73 million, a price-to-earnings ratio of -8.63 and a beta of 1.07.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms recently commented on ELVN. Jones Trading lowered their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th. HC Wainwright raised their target price on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $37.25.
Get Our Latest Report on ELVN
Insider Activity
In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the sale, the chief operating officer now owns 323,310 shares in the company, valued at $6,931,766.40. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at $265,330. The trade was a 20.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 86,111 shares of company stock worth $1,657,145. 29.20% of the stock is currently owned by corporate insiders.
About Enliven Therapeutics
(
Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
